title: Selenium protects the immature rat heart against ischemia/reperfusion injury.
abstract: The aim of the study was to find out whether administration of selenium (Se) will protect the immature heart against ischemia/reperfusion.The control pregnant rats were fed laboratory diet (0.237 mg Se/kg diet); experimental rats received 2 ppm Na(2)SeO(3) in the drinking water from the first day of pregnancy until day 10 post partum. The concentration of Se in the serum and heart tissue was determined by activation analysis, the serum concentration of NO by chemiluminescence, cardiac concentration of lipofuscin-like pigment by fluorescence analysis. The 10 day-old hearts were perfused (Langendorff); recovery of developed force (DF) was measured after 40 min of global ischemia. In acute experiments, 10 day-old hearts were perfused with selenium (75 nmol/l) before or after global ischemia. Sensitivity to isoproterenol (ISO, pD(50)) was assessed as a response of DF to increasing cumulative dose.Se supplementation elevated serum concentration of Se by 16%. Se increased ischemic tolerance (recovery of DF, 32.28 +/- 2.37 vs. 41.82 +/- 2.91%, P < 0.05). Similar results were obtained after acute administration of Se during post-ischemic reperfusion (32.28 +/- 2.37 vs. 49.73 +/- 4.40%, P < 0.01). The pre-ischemic treatment, however, attenuated the recovery (23.08 +/- 3.04 vs. 32.28 +/- 2.37%, P < 0.05). Moreover, Se supplementation increased the sensitivity to the inotropic effect of ISO, decreased cardiac concentration of lipofuscin-like pigment and serum concentration of NO. Our results suggest that Se protects the immature heart against ischemia/reperfusion injury. It seems therefore, that ROS may affect the function of the neonatal heart, similarly as in adults.
authors.affiliation: Centre of Cardiovascular Research, Institute of Physiology, Academy of Sciences of the Czech Republic, Vídenská 1083, 142 20 Prague 4-Krc, Czech Republic. iostadal@biomed.cas.cz
authors.forename: Ivana
authors.initials: I
authors.lastname: Ostadalova
authors.forename: Miloslav
authors.initials: M
authors.lastname: Vobecky
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Chvojkova
authors.forename: Dana
authors.initials: D
authors.lastname: Mikova
authors.forename: Vaclav
authors.initials: V
authors.lastname: Hampl
authors.forename: Jiri
authors.initials: J
authors.lastname: Wilhelm
authors.forename: Bohuslav
authors.initials: B
authors.lastname: Ostadal
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D019587:Dietary Supplements; D005260:Female; D006321:Heart / Q000187:drug effects*; D008062:Lipofuscin / Q000378:metabolism; D009200:Myocardial Contraction / Q000187:drug effects; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000517:prevention & control*; D009569:Nitric Oxide / Q000097:blood; D009929:Organ Size / Q000187:drug effects; D010477:Perfusion; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar; D012643:Selenium / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D008062:Lipofuscin; D009569:Nitric Oxide; D012643:Selenium